Based in Ocala, Florida, Biologic Therapies, Inc. (BTI) is a company with a principal strategy of seeking out and developing innovative, proprietary and patented technologies to meet the needs of the emerging biologics / regenerative medicine healthcare market. Biologic Therapies’ mission is to provide groundbreaking medical technologies that significantly enhance the body’s natural healing ability, thereby providing patients with improved outcomes and quicker restoration of function. The Company’s initial products provide access to the biologics sector of the well established and rapidly growing field of orthopedics. BTI is a leading provider of medical devices and systems for regenerative cell therapy.
Biologic Therapies provides contemporary, pioneering technologies that enable surgeons to treat numerous orthopedic and other medical challenges. One such technology is BTI’s unique Bio-MAC® Bone Marrow Aspiration Cannula, provisional patent number 61/445,624, U.S. patent pending.
Biologic Therapies utilizes advanced medical research to open direct paths to technologies for regenerative cell therapy, which refers to using the body’s own regenerative cells that self-renew, have the ability to change into other types of cells, and accelerate healing. BTI develops proprietary products and surgical protocols designed to optimize this type of therapy. BTI’s state-of-the-art products are propelling the Company as an industry leader by implementing a new ‘Standard of Care’ with its products and system technologies.
Regenerative medicine is a relatively new medical science that focuses on the body's own regenerative cells’ ability to speed healing within muscle, tendon, ligament, bone and cartilage. This exciting, emerging technology is in its pioneering stage with tremendous growth potential. Its expansion and the number of technologies and treatments for patients both young and old will continue as more is learned and confidence is built through continued research and clinical experience. BTI’s selection of regenerative cell therapy products is based on their utility, profitability and patentability.
Biologic Therapies believes considerable opportunities exist within the high growth niche sector of minimally invasive surgery (MIS). Demographics of an aging population worldwide, increased healthcare demand, and recent sales growth of medical device companies reflects a unique opportunity for creating value within this segment. BTI’s products, systems and procedures are specifically designed to enhance the use of autologous biologic cell therapy throughout the MIS sector.
Biologic Therapies’ leadership structure is based on extensive industry experience, longstanding relationships with leading physicians, and established sales and distribution channels. As BTI continues to research and develop new and simple, yet elegant ways to solve complex medical problems, the Company has become known as a technology innovator.
In today’s information age, patients are becoming much more knowledgeable about emerging medical trends and available techniques. Therefore, BTI has embraced the responsibility of providing innovative, contemporary marketing solutions to assist physicians in meeting their patients’ requests, needs and expectations.
Biologic Therapies brings new products to the market based on the needs of the medical community, the needs of patients, and the business requirements of the Company. This strategic methodology ensures that BTI selects appropriate technologies for development and thereby provide the best opportunity for success.
Regenerative cell therapy has been identified as a major developing segment within the multi-billion dollar regenerative medicine market. New breakthroughs and clinical successes in regenerative cell therapy are helping guide Biologic Therapies as it introduces proprietary, innovative products. This strategy ensures the Company’s success of selecting appropriate technologies for development.
BTI’s innovative Bio-MAC® Bone Marrow Aspiration Cannula and associated Bio-SPINTM centrifuge system are fueling the Company’s growth and are affirming Biologic Therapies as a global leader in regenerative medicine. New products include the Bio-PLASTYTM Intraosseous Injection Cannula and the Bio-CORETM Bone Marrow Biopsy Cannula.
Biologic Therapies’ mission is to provide proprietary, groundbreaking medical technologies that significantly enhance the body's ability to utilize it's own properties to increase healing and provide quicker restoration of function.
Biologic Therapies has a very comprehensive Quality Policy based on ISO 13485 policies and standards, which helps ensure the Company’s success as it grows and introduces more products and services. BTI is committed to continuous quality improvement in all its policies and procedures.